An investigation has commenced on behalf of vertex pharmaceuticals incorporated shareholders. contact levi & korsinsky to discuss your vrtx losses.

New york, ny / access newswire / february 5, 2025 / levi & korsinsky notifies investors that it has commenced an investigation of vertex pharmaceuticals incorporated ("vertex pharmaceuticals") (nasdaq:vrtx) concerning possible violations of federal securities laws. on december 19, 2024, the company reported disappointing results from its rewind-lb phase 2b clinical trial for the pain drug suzetrigine.
VRTX Ratings Summary
VRTX Quant Ranking